Reports of medication-related osteonecrosis of the jaw develop across an extended time frame rather than clustering solely during the initial stages of therapy, according to research evaluating national pharmacovigilance records alongside clinical cohort observations. The investigation, which combined broad database tracking with single-center clinical records, analyzed temporal patterns linked to bone-modifying agents and other therapies. Researchers evaluated how reported onset intervals differ across specific patient indications and therapeutic agents to clarify when adverse outcomes emerge during medical treatment.
The study addressed medication-related osteonecrosis of the jaw, recognized as a rare but serious adverse event associated with bone-modifying agents and related interventions. Because the precise time-to-onset characteristics of the condition have not been fully elucidated, the research team structured a complementary investigation integrating a spontaneous reporting system with direct clinical observations. By evaluating both pharmacovigilance reports and patient records, the study aimed to evaluate reported onset timing and analyze underlying temporal trajectories across diverse treatment settings.
For the primary pharmacovigilance evaluation, researchers analyzed reports recorded in the Japanese Adverse Drug Event Report database, applying Weibull distribution analysis to model temporal onset patterns over time. To complement the registry findings with direct real-world care patterns, the investigators also conducted a supportive retrospective cohort study at a single medical center. This observational cohort focused on patients diagnosed with lung cancer, providing supportive clinical data regarding the frequency of osteonecrosis of the jaw, observed time to onset, and clinical management pathways.
Analysis of the national database revealed that reports of jaw osteonecrosis exhibited a broad time-to-onset distribution instead of clustering exclusively within the early treatment period. Furthermore, Weibull distribution analysis indicated that adverse event reports were not restricted to any single time window during therapy. The timing of reported onset differed significantly between clinical indications, with adverse events tending to be reported significantly earlier among patients treated for malignancy compared with individuals receiving treatment for osteoporosis.
The pharmacovigilance data also demonstrated notable variations across specific therapeutic agents. Among medications prescribed for osteoporosis, the time to reported adverse event onset exhibited statistically significant differences across individual agents. Conversely, within the malignancy group, statistical evaluations showed no significant difference in reported onset timing when comparing patients treated with zoledronic acid against those who received denosumab, indicating similar timing patterns between the two bone-modifying therapies in oncological care.
Direct observations from the single-center lung cancer cohort provided supportive real-world metrics regarding disease frequency and clinical detection. Among all patients receiving pharmacological treatment for lung cancer, the observed proportion of medication-related osteonecrosis of the jaw was 1.5 percent. When restricted specifically to patients receiving bone-modifying agents, the observed proportion was 4.4 percent, whereas among denosumab recipients the proportion reached 5.8 percent. Across this cohort, the median interval from initiation of bone-modifying therapy to the onset of jaw osteonecrosis was approximately 38 months.
Clinical management details within the cohort revealed that most cases of jaw osteonecrosis were initially detected during examinations at community dental clinics before patients were referred for specialist care. While absolute time-to-onset estimates differed between the pharmacovigilance registry and the single-center clinical dataset, both evidence sources consistently demonstrated that onset is distributed over a broad time range. These combined observations indicate that long-term pharmaceutical care, patient education, continuous oral monitoring, and collaborative dental care provider partnerships remain necessary throughout ongoing bone-modifying treatment.
The statistical analyses of the JADER database provided key significance values, showing that reports of jaw osteonecrosis emerged significantly earlier in the malignancy group than in the osteoporosis group (p < 0.001). Onset timing also differed significantly among individual agents prescribed for osteoporosis (p < 0.001). In contrast, researchers detected no statistically significant difference between zoledronic acid and denosumab in the malignancy group, indicating consistent onset timing between these two oncological therapies.
Integrating spontaneous adverse drug event reports with clinical observations helped clarify temporal patterns that were previously not fully elucidated. Because Weibull distribution analysis indicated that onset is distributed across a broad time range rather than restricted to a particular period, the findings reinforce the necessity of patient education and ongoing collaboration with dental care providers throughout long-term bone-modifying therapy.
Subject of Research: Temporal onset patterns and clinical characteristics of medication-related osteonecrosis of the jaw
Article Title: Time-to-onset patterns of medication-related osteonecrosis of the jaw: a JADER database study with supportive single-center observations
Article References: Toriumi, S., Morikawa, A., Kurihara, Y., Shimokawa, K., Tanaka, A., Araki, N., Kawai, O., & Uesawa, Y. (2026). Time-to-onset patterns of medication-related osteonecrosis of the jaw: a JADER database study with supportive single-center observations. Journal of Pharmaceutical Health Care and Sciences. https://doi.org/10.1186/s40780-026-00633-8
Image Credits: AI Generated
DOI: 10.1186/s40780-026-00633-8
Keywords: medication-related osteonecrosis of the jaw, bone-modifying agents, JADER database, Weibull distribution analysis, pharmacovigilance, denosumab, zoledronic acid, lung cancer, osteoporosis, adverse drug reactions, time-to-onset analysis, oral monitoring, dental care collaboration, retrospective cohort study, oncology, clinical pharmacy
News Source: Nathaniel Bowman. (November 18, 2026). Bone-Modifying Agent Reports Reveal Broad Time-to-Onset Window for Jaw Osteonecrosis. Scienmag.



